CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma

BJU Int. 2021 Jul;128(1):29-32. doi: 10.1111/bju.15341. Epub 2021 Feb 7.

Authors

Gennadi Tulchiner¹, Andrea Brunner², Manuela Schmidinger³, Nina Staudacher¹, Jacob J Orme⁴, Martin Thurnher¹, Wolfgang Horninger¹, Zoran Culig¹, Renate Pichler¹

Affiliations

¹ Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
² Department of Pathology, Neuropathology and Molecular Pathology, Medical University Innsbruck, Innsbruck, Austria.
³ Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
⁴ Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

No abstract available

MeSH terms

Biomarkers, Tumor / biosynthesis*
Carcinoma, Renal Cell / metabolism*
Carcinoma, Renal Cell / secondary
Carcinoma, Renal Cell / therapy*
Humans
Immunotherapy*
Kidney Neoplasms / metabolism*
Kidney Neoplasms / pathology
Kidney Neoplasms / therapy*
MARVEL Domain-Containing Proteins / biosynthesis*
Myelin Proteins / biosynthesis*

Substances

Biomarkers, Tumor
CMTM6 protein, human
MARVEL Domain-Containing Proteins
Myelin Proteins